Navigation Links
SuperGen Reports 2008 Third Quarter Financial Results
Date:11/4/2008

Royalty Revenue Increases 67% from Same Prior Year Period

DUBLIN, Calif., Nov. 4 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced financial results for the third quarter and nine months ended September 30, 2008.

Total revenues for the 2008 third quarter were $10.2 million compared with $6.1 million for the same prior year period. Total revenues for the 2008 third quarter and same prior year period consist entirely of royalty revenue. Royalty revenue is earned pursuant to the license agreement entered into with MGI PHARMA (acquired by Eisai Co., Ltd. in January 2008) during 2004, which granted the licensee exclusive rights to the development, manufacture, commercialization and distribution of Dacogen(R) (decitabine) for Injection. The Company recognizes royalty revenue on a cash basis when it is received.

Excluding gain on sale of products, total costs and operating expenses for the 2008 third quarter were $11.4 million, compared with $9.2 million for the same prior year period. The primary reason for the increase in total costs and operating expenses for the 2008 third quarter were higher research and development costs related to increased product development activities including ongoing clinical operations and the payment of additional severance costs in the amount of $98,000 related to the closure of our European operations offset in part by a reduction in general and administrative expenses related to the cessation of our European operations and lower stock-based compensation expense. The closure of the European operations was effective October 1, 2008 and is anticipated will reduce future ope
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. SuperGen Reports 2008 Second Quarter Financial Results
10. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
11. SuperGen to Present Data at EORTC-NCI-AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013   NineSigma , Inc., of ... following its launch, NineSights.com is now the ... for the worldwide community of innovators. From ... sustainability experts, NineSights stands out for its large community ... and technical disciplines, all vetted by NineSigma. The community ...
(Date:6/19/2013)... Atlanta (PRWEB) June 19, 2013 Today ... urged young people to become leaders in the greatest ... 9 billion people in 2050. Borel spoke at ... Conference in Atlanta, about urgent need for students ... that are local, science-based, sustainable and reached in collaboration ...
(Date:6/19/2013)... June 19, 2013 ... presents Innovative Drug Delivery Systems: ... Licensing Opportunities for Generic Pharmaceutical ... There are more than ... drugs approved all over the ...
(Date:6/19/2013)... India’s vast and growing population means ... up to a billion dollars per year by ... taking serious action to better regulate and oversee ... will examine:, ,     Recent changes in ... long term impacts ,     Foreseeable opportunities ...
Breaking Biology Technology:NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3
... revolutionary surgical instrument system that is smaller in diameter than a ... implantation of the VerteLoc™ Minimally Invasive Spine Stabilization System and will ... Arizona starting on March 12, 2009. , ... Winston-Salem, ...
... In ClearTrial v2.7, the newest version of ... Portfolio Planning capability which enables clinical development ... into portfolio-level forecasts in minutes. The ... monthly resource demand, and timelines across a ...
... Enobia Pharma, an emerging Canadian biotech company ... disorders, today announced completion of target enrollment in ... a severe form of hypophosphatasia. Enobia is ... the treatment of this rare and often crippling ...
Cached Biology Technology:VGI Announces the Launch of DISMISS Instruments for the VerteLoc™ Minimally Invasive Spine Stabilization System 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 3ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 4Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 2Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 3
(Date:6/19/2013)... Medicines Agency (EMA) approved the modified adeno-associated virus ... for clinical use in the Western world. uniQure, ... for the treatment of a rare inherited metabolic ... approximately one or two out of one million ... the pancreas. Afflicted individuals carry a defect in ...
(Date:6/18/2013)... from the United Kingdom, the Energy Department,s National ... Kentucky have recently published a paper describing a ... Limnoria quadripunctata , commonly known as the ... they exhibit a relatively unique ability to produce ... to break down the biomass they eat. New ...
(Date:6/18/2013)... of Molecular Biology, has been honored as a ... Torrent is being recognized for his outstanding research, ... antimicrobial regions in proteins. Luis Rivas, Centro de ... algorithm to interrogate full genomes in order to ... results." , Torrent obtained his Ph.D. from ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2The American Society for Microbiology honors Marc Torrent 2
... an inherited genetic basis for racial and ethnic disparities ... increased risk of relapse in young leukemia patients. The ... Research Hospital and the Children,s Oncology Group (COG). ... new marker of poor treatment outcome, researchers reported evidence ...
... N.C. Everyone knows chocolate is critical to a happy Valentine,s ... a heart happy the rest of the year. It,s a ... DOT1L enzyme, you could be at risk for some types of ... the University of North Carolina at Chapel Hill School of Medicine ...
... Reserve University have developed a little bomb that promises a ... an anti-cancer drug loosely attached to gold nanoparticles starts accumulating ... activated for an effective treatment within two hours. The same ... the tumor from the surface a far less effective ...
Cached Biology News:Native American ancestry linked to greater risk of relapse in young leukemia patients 2Native American ancestry linked to greater risk of relapse in young leukemia patients 3Just in time for Valentine's Day: UNC researchers identify a gene critical for heart function 2A loose grip provides better chemotherapy 2
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
WTAP Antibody...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: